Cisplatin + Irinotecan

Indication

Esophageal Cancer

Chemotherapy for stage IV (metastatic) cancer

• Cisplatin 30 mg/m2 iv
• Irinotecan (CPT-11) 65 mg/m2 iv
• Qw

References

Ilson, DH et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999; 17:3270

Gastric Cancer

Chemotherapy for locally advanced unresectable and metastatic cancer

• Cisplatin 30 mg/m2 iv d1
• Irinotecan (CPT-11) 65 mg/m2 iv d1
• Qw for 4 wks every 6 wks

References

Ajani, JA et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 2002; 94:641

Lung Cancer Small Cell

Extensive stage

Regimen 1

• Cisplatin 60 mg/m2 iv d1
• Irinotecan (Camptosar, CPT-11) 60 mg/m2 iv d1, 8 and 15
• Q4w x 4 cycles

References

Noda K et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Eng J Med 2002; 346:85

Regimen 2

• Cisplatin 30 mg/m2 iv d1, 8
• Irinotecan (Camptosar, CPT-11) 65 mg/m2 iv d1, 8
• Q3w

References

Hanna N et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006; 24:2038